Rich Insights into the Endometrial Cancer Pipeline and Clinical Trial Analysis Featuring 5+ Companies and Therapies

 Breaking News
  • No posts were found

Rich Insights into the Endometrial Cancer Pipeline and Clinical Trial Analysis Featuring 5+ Companies and Therapies

March 07
17:32 2023
Rich Insights into the Endometrial Cancer Pipeline and Clinical Trial Analysis Featuring 5+ Companies and Therapies

DelveInsight’s, “Endometrial Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Endometrial Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Endometrial Cancer Emerging drugs, the Endometrial Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Endometrial Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Endometrial Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Endometrial Cancer clinical trials studies, Endometrial Cancer NDA approvals (if any), and product development activities comprising the technology, Endometrial Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Endometrial Cancer Pipeline Insight Report

 

  • DelveInsight’s Endometrial Cancer Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.

 

  • The leading Endometrial Cancer Companies includes GlaxoSmithKline, Eisai Co Ltd, MedImmune, On Target Laboratories, Sutro Biopharma, Netris Pharma, and others.

 

  • Promising Endometrial Cancer Pipeline Therapies includes ridaforolimus, Lenvatinib, BN83495, Megestrol Acetate (MA), brachytherapy, arzoxifene hydrochloride, Selinexor, Letrozole, ONC201, AEZS-108 / zoptarelin doxorubicin, doxorubicin, oxaliplatin, 5 FU, and others.

 

  • The Endometrial Cancer companies and academics are working to assess challenges and seek opportunities that could influence Endometrial Cancer R&D. The Endometrial Cancer pipeline therapies under development are focused on novel approaches to treat/improve Endometrial Cancer.

 

Request a sample and discover the recent breakthroughs happening in the Endometrial Cancer Pipeline landscape @ Endometrial Cancer Pipeline Outlook Report

 

Endometrial Cancer Overview

Endometrial cancer is cancer of the endometrium, which is the lining of the uterus. It is the most common type of cancer that affects the female reproductive organs. The most common type of endometrial cancer (type 1) grows slowly. It most often is found only inside the uterus. Type 2 is less common. It grows more rapidly and tends to spread to other parts of the body. Endometrial cancer occurs when the cells of the endometrium start to grow too rapidly. The lining of the uterus may thicken in certain places. These areas of thickness may form a mass of tissue called a tumor. Cancer cells also can spread (metastasize) to other areas of the body.

 

Endometrial Cancer Emerging Drugs Profile

 

  • Dostarlimab: GlaxoSmithKline

Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. The drug is in pre-registration stage of development for the treatment of Endometrial cancer.

 

  • Lenvatinib (LENVIMA): Eisai Co Ltd

LENVIMA is an orally administered kinase inhibitor with a novel binding mode that selectively inhibits the multi activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRα; KIT; and RET) involved in tumor angiogenesis, tumor progression and modification of tumor immunity. The drug is registered for the treatment of endometrial cancer.

 

For further information, refer to the detailed Endometrial Cancer Drugs Launch, Endometrial Cancer Developmental Activities, and Endometrial Cancer News, click here for Endometrial Cancer Ongoing Clinical Trial Analysis

 

Endometrial Cancer Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for Endometrial Cancer. The companies which have their Endometrial Cancer drug candidates in the mid to advanced stage, i.e. preregistration include GlaxoSmithKline.

 

Endometrial Cancer Pipeline

Phases

  • Late-stage products (phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Find out more about the Endometrial Cancer Pipeline Segmentation, Therapeutics Assessment, and Endometrial Cancer Emerging Drugs @ Endometrial Cancer Treatment Landscape

 

Scope of the Endometrial Cancer Pipeline Report

 

  • Coverage- Global

 

  • Endometrial Cancer Companies- GlaxoSmithKline, Eisai Co Ltd, MedImmune, On Target Laboratories, Sutro Biopharma, Netris Pharma, and others.

 

  • Endometrial Cancer Pipeline Therapies- ridaforolimus, Lenvatinib, BN83495, Megestrol Acetate (MA), brachytherapy, arzoxifene hydrochloride, Selinexor, Letrozole, ONC201, AEZS-108 / zoptarelin doxorubicin, doxorubicin, oxaliplatin, 5 FU, and others.

 

  • Endometrial Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Endometrial Cancer Pipeline Companies and Therapies, click here @ Endometrial Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Endometrial Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Endometrial Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Endometrial Cancer Collaboration Deals
  9. Late Stage Products (Preregistration)
  10. Dostarlimab: GlaxoSmithKline
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Pafolacianine: On Target Laboratories
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. STRO 002: Sutro Biopharma
  17. Drug profiles in the detailed report…..
  18. Endometrial Cancer- Market Drivers and Barriers
  19. Endometrial Cancer- Future Perspectives and Conclusion
  20. Endometrial Cancer Analyst Views
  21. Endometrial Cancer Key Companies
  22. Appendix

 

Got Queries? Find out the related information on Endometrial Cancer Mergers and acquisitions, Endometrial Cancer Licensing Activities @ Endometrial Cancer Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/